1. [Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM.]
- Author
-
Dettori, I, Ladaique, P, Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang - Alpes-Méditerranée (EFS - Alpes-Méditerranée), Etablissement Français du Sang, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), and Dubois Frid, Caroline
- Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology ,Blood Platelets ,Academies and Institutes ,Hospital Departments ,Disease Management ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,Platelet Transfusion ,Allografts ,Medical Oncology ,Thrombocytopenia ,Interinstitutional Relations ,Isoantibodies ,Hematologic Neoplasms ,Blood Banks ,Humans ,Antigens, Human Platelet ,Immunization ,France ,Spleen ,Bone Marrow Transplantation - Abstract
International audience; The platelet refractoriness is a complication of transfusion treatments potentially dramatic in onco-haematology. Chemo-treatment of haematological malignancies or packs of allogeneic bone marrow transplants require iterative platelet transfusion requirements. The discovery of a platelet refractoriness along with its support should be the most reactive as possible but also adapted to the cause. In the case of allo-immunization, it may be expected. The purpose of this presentation is to recall the different etiologies and perform a feedback on the support transfusion platelet of onco-haematology adult patients at Institut Paoli-Calmettes (IPC) in partnership with the EFSAM.
- Published
- 2014